Cellular Aging Secretes: a Comparison of Bone-Marrow-Derived and Induced Mesenchymal Stem Cells and Their Secretome Over Long-Term Culture.
Bone marrow
Human platelet lysate
Induced pluripotent stem cells
Mesenchymal stem cells
Replicative senescence
Secretome
Senescence-associated secretory profile
Journal
Stem cell reviews and reports
ISSN: 2629-3277
Titre abrégé: Stem Cell Rev Rep
Pays: United States
ID NLM: 101752767
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
09
09
2022
pubmed:
25
9
2022
medline:
11
1
2023
entrez:
24
9
2022
Statut:
ppublish
Résumé
Mesenchymal stem cells (MSCs) hold promising therapeutic potential in several clinical applications, mainly due to their paracrine activity. The implementation of future secretome-based therapeutic strategies requires the use of easily accessible MSCs sources that provide high numbers of cells with homogenous characteristics. MSCs obtained from induced pluripotent stem cells (iMSCs) have been put forward as an advantageous alternative to the gold-standard tissue sources, such as bone marrow (BM-MSCs). In this study, we aimed at comparing the secretome of BM-MSCs and iMSCs over long-term culture. For that, we performed a broad characterization of both sources regarding their identity, proteomic secretome analysis, as well as replicative senescence and associated phenotypes, including its effects on MSCs secretome composition and immunomodulatory action. Our results evidence a rejuvenated phenotype of iMSCs, which is translated into a superior proliferative capacity before the induction of replicative senescence. Despite this significant difference between iMSCs and BM-MSCs proliferation, both untargeted and targeted proteomic analysis revealed a similar secretome composition for both sources in pre-senescent and senescent states. These results suggest that shifting from the use of BM-MSCs to a more advantageous source, like iMSCs, may yield similar therapeutic effects as identified over the past years for this gold-standard MSC source.
Identifiants
pubmed: 36152233
doi: 10.1007/s12015-022-10453-6
pii: 10.1007/s12015-022-10453-6
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
248-263Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Caplan, A. I. (1991). Mesenchymal stem cells. Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society, 9(5), 641–650. https://doi.org/10.1002/jor.1100090504
doi: 10.1002/jor.1100090504
Pittenger, M. F., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143–147.
doi: 10.1126/science.284.5411.143
Caplan, A. I., & Dennis, J. E. (2006). Mesenchymal stem cells as trophic mediators. Journal of Cellular Biochemistry, 98(5), 1076–1084. https://doi.org/10.1002/jcb.20886
doi: 10.1002/jcb.20886
Teixeira, F. G., et al. (2013). Mesenchymal stem cells secretome: A new paradigm for central nervous system regeneration? Cellular and Molecular Life Sciences, 70(20), 3871–3882. https://doi.org/10.1007/s00018-013-1290-8
Marote, A., et al. (2016). MSCs-derived exosomes: Cell-secreted nanovesicles with regenerative potential. Frontiers in Pharmacology, 7(231). https://doi.org/10.3389/fphar.2016.00231
Teixeira, F. G., et al. (2017). Impact of the secretome of human mesenchymal stem cells on brain structure and animal behavior in a rat model of parkinson’s disease. Stem Cells Translational Medicine, 6(2), 634–646. https://doi.org/10.5966/sctm.2016-0071
doi: 10.5966/sctm.2016-0071
Mendes-Pinheiro, B., et al. (2019). Bone marrow mesenchymal stem cells’ secretome exerts neuroprotective effects in a parkinson’s disease rat model. Frontiers in Bioengineering and Biotechnology, 7, 294–294. https://doi.org/10.3389/fbioe.2019.00294
doi: 10.3389/fbioe.2019.00294
Cunningham, C. J., et al. (2018). The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 38(8), 1276–1292. https://doi.org/10.1177/0271678x18776802
doi: 10.1177/0271678x18776802
Timmers, L., et al. (2007). Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Research, 1(2), 129–137. https://doi.org/10.1016/j.scr.2008.02.002
doi: 10.1016/j.scr.2008.02.002
Nazarie Ignat, S.-R., et al. (2021). Regenerative potential of Mesenchymal Stem Cells’ (MSCs) secretome for liver fibrosis therapies. International Journal of Molecular Sciences, 22(24), 13292. https://doi.org/10.3390/ijms222413292
doi: 10.3390/ijms222413292
Wruck, W., et al. (2021). Human Induced pluripotent stem cell-derived mesenchymal stem cells acquire rejuvenation and reduced heterogeneity. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.717772
Zhang, J., et al. (2021). Induced pluripotent stem cell-derived mesenchymal stem cells hold lower heterogeneity and great promise in biological research and clinical applications. Frontiers in Cell and Developmental Biology, 9, 716907–716907. https://doi.org/10.3389/fcell.2021.716907
doi: 10.3389/fcell.2021.716907
Spitzhorn, L.-S., et al. (2019). Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature. Stem Cell Research & Therapy, 10(1), 100. https://doi.org/10.1186/s13287-019-1209-x
doi: 10.1186/s13287-019-1209-x
Fernandez-Rebollo, E., et al. (2020). Senescence-associated metabolomic phenotype in primary and iPSC-derived mesenchymal stromal cells. Stem Cell Reports, 14(2), 201–209. https://doi.org/10.1016/j.stemcr.2019.12.012
doi: 10.1016/j.stemcr.2019.12.012
Frobel, J., et al. (2014). Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Reports, 3(3), 414–422. https://doi.org/10.1016/j.stemcr.2014.07.003
doi: 10.1016/j.stemcr.2014.07.003
Lian, Q., et al. (2010). Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation, 121(9), 1113–1123.
doi: 10.1161/CIRCULATIONAHA.109.898312
Kimbrel, E. A., et al. (2014). Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells and Development, 23(14), 1611–1624. https://doi.org/10.1089/scd.2013.0554
doi: 10.1089/scd.2013.0554
Jungbluth, P., et al. (2019). Human iPSC-derived iMSCs improve bone regeneration in mini-pigs. Bone Research, 7, 32–32. https://doi.org/10.1038/s41413-019-0069-4
doi: 10.1038/s41413-019-0069-4
Bloor, A. J. C., et al. (2020). Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: A phase I, multicenter, open-label, dose-escalation study. Nature Medicine, 26(11), 1720–1725. https://doi.org/10.1038/s41591-020-1050-x
doi: 10.1038/s41591-020-1050-x
Hayflick, L. (1965). The limited in vitro lifetime of human diploid cell strains. Experimental Cell Research, 37(3), 614–636. https://doi.org/10.1016/0014-4827(65)90211-9
doi: 10.1016/0014-4827(65)90211-9
Kumari, R., & Jat, P. (2021). Mechanisms of cellular senescence: Cell cycle arrest and senescence associated secretory phenotype. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.645593
Anjo, S. I., et al. (2019). Use of recombinant proteins as a simple and robust normalization method for untargeted proteomics screening: exhaustive performance assessment. Talanta, 205, 120163. https://doi.org/10.1016/j.talanta.2019.120163
doi: 10.1016/j.talanta.2019.120163
Anjo, S. I., et al. (2015). Short GeLC-SWATH: A fast and reliable quantitative approach for proteomic screenings. Proteomics, 15(4), 757–762. https://doi.org/10.1002/pmic.201400221
doi: 10.1002/pmic.201400221
Gillet, L. C., et al. (2012). Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis*. Molecular & Cellular Proteomics, 11(6), O111.016717. https://doi.org/10.1074/mcp.O111.016717
doi: 10.1074/mcp.O111.016717
Sennels, L., et al. (2009). Improved results in proteomics by use of local and peptide-class specific false discovery rates. BMC Bioinformatics, 10, 179–179. https://doi.org/10.1186/1471-2105-10-179
doi: 10.1186/1471-2105-10-179
Tang, W. H., et al. (2008). Nonlinear fitting method for determining local false discovery rates from decoy database searches. Journal of Proteome Research, 7(9), 3661–3667. https://doi.org/10.1021/pr070492f
doi: 10.1021/pr070492f
Lambert, J.-P., et al. (2013). Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition. Nature methods, 10(12), 1239–1245. https://doi.org/10.1038/nmeth.2702
doi: 10.1038/nmeth.2702
Collins, B. C., et al. (2013). Quantifying protein interaction dynamics by SWATH mass spectrometry: Application to the 14–3-3 system. Nature Methods, 10(12), 1246–1253. https://doi.org/10.1038/nmeth.2703
doi: 10.1038/nmeth.2703
Jung, S., et al. (2000). Analysis of fractalkine receptor CX
doi: 10.1128/MCB.20.11.4106-4114.2000
Richner, M., et al. (2017). Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents. Journal of visualized experiments: JoVE(119), 55226. https://doi.org/10.3791/55226
Dominici, M., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy, 8(4), 315–317. https://doi.org/10.1080/14653240600855905
doi: 10.1080/14653240600855905
Mark, P., et al. (2013). Human mesenchymal stem cells display reduced expression of CD105 after culture in serum-free medium. Stem Cells International, 2013, 698076–698076. https://doi.org/10.1155/2013/698076
doi: 10.1155/2013/698076
Anderson, P., et al. (2013). CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities. PLoS ONE, 8(10), e76979–e76979. https://doi.org/10.1371/journal.pone.0076979
doi: 10.1371/journal.pone.0076979
Grau-Vorster, M., et al. (2019). HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: A two-site study. Stem Cell Research & Therapy, 10(1), 164. https://doi.org/10.1186/s13287-019-1279-9
doi: 10.1186/s13287-019-1279-9
Assuncao-Silva, R. C., et al. (2018). Exploiting the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth. Biochimie, 155, 83–91. https://doi.org/10.1016/j.biochi.2018.1007.1026
doi: 10.1016/j.biochi.2018.1007.1026
Pires, A. O., et al. (2016). Unveiling the differences of secretome of human bone marrow mesenchymal stem cells, adipose tissue-derived stem cells, and human umbilical cord perivascular cells: A proteomic analysis. Stem Cells and Development, 25(14), 1073–1083. https://doi.org/10.1089/scd.2016.0048
doi: 10.1089/scd.2016.0048
Kehl, D., et al. (2019). Proteomic analysis of human mesenchymal stromal cell secretomes: A systematic comparison of the angiogenic potential. npj Regenerative Medicine, 4(1), 8. https://doi.org/10.1038/s41536-019-0070-y
doi: 10.1038/s41536-019-0070-y
Salama, R., et al. (2014). Cellular senescence and its effector programs. Genes & Development, 28(2), 99–114. https://doi.org/10.1101/gad.235184.113
doi: 10.1101/gad.235184.113
Di Micco, R., et al. (2021). Cellular senescence in ageing: From mechanisms to therapeutic opportunities. Nature Reviews. Molecular Cell Biology, 22(2), 75–95. https://doi.org/10.1038/s41580-020-00314-w
doi: 10.1038/s41580-020-00314-w
Copland, I. B., et al. (2013). The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials, 34(32), 7840–7850. https://doi.org/10.1016/j.biomaterials.2013.06.050
doi: 10.1016/j.biomaterials.2013.06.050
Galland, S., & Stamenkovic, I. (2020). Mesenchymal stromal cells in cancer: A review of their immunomodulatory functions and dual effects on tumor progression. The Journal of pathology, 250(5), 555–572. https://doi.org/10.1002/path.5357
doi: 10.1002/path.5357
Pinho, A. G., et al. (2020). Cell secretome: Basic insights and therapeutic opportunities for CNS disorders. Pharmaceuticals (Basel), 13(2), E31. https://doi.org/10.3390/ph13020031
doi: 10.3390/ph13020031
Ferreira, J. R., et al. (2018). Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular pre-conditioning. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.02837
Levy, O., et al. (2020). Shattering barriers toward clinically meaningful MSC therapies. Science Advances, 6(30), eaba6884. https://doi.org/10.1126/sciadv.aba6884
doi: 10.1126/sciadv.aba6884
Teixeira, F. G., et al. (2015). Do hypoxia/normoxia culturing conditions change the neuroregulatory profile of Wharton Jelly mesenchymal stem cell secretome? Stem Cell Research & Therapy, 6, 133. https://doi.org/10.1186/s13287-015-0124-z
doi: 10.1186/s13287-015-0124-z
Moerman, E. J., et al. (2004). Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: The role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell, 3(6), 379–389. https://doi.org/10.1111/j.1474-9728.2004.00127.x
doi: 10.1111/j.1474-9728.2004.00127.x
Jiao, H., et al. (2021). GATA6 regulates aging of human mesenchymal stem/stromal cells. Stem Cells, 39(1), 62–77. https://doi.org/10.1002/stem.3297
doi: 10.1002/stem.3297
Hemeda, H., et al. (2014). Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy, 16(2), 170–180. https://doi.org/10.1016/j.jcyt.2013.11.004
doi: 10.1016/j.jcyt.2013.11.004
Reis, M., et al. (2018). Global phenotypic characterisation of human platelet lysate expanded MSCs by high-throughput flow cytometry. Scientific Reports, 8(1), 3907. https://doi.org/10.1038/s41598-018-22326-5
doi: 10.1038/s41598-018-22326-5
McGrath, M., et al. (2019). GMP-compatible and xeno-free cultivation of mesenchymal progenitors derived from human-induced pluripotent stem cells. Stem Cell Research & Therapy, 10(1), 11. https://doi.org/10.1186/s13287-018-1119-3
doi: 10.1186/s13287-018-1119-3
Becherucci, V., et al. (2018). Human platelet lysate in mesenchymal stromal cell expansion according to a GMP grade protocol: A cell factory experience. Stem Cell Research & Therapy, 9(1), 124. https://doi.org/10.1186/s13287-018-0863-8
doi: 10.1186/s13287-018-0863-8
Wang, L.-T., et al. (2018). Differentiation of mesenchymal stem cells from human induced pluripotent stem cells results in downregulation of c-Myc and DNA replication pathways with immunomodulation toward CD4 and CD8 cells. Stem Cells, 36(6), 903–914. https://doi.org/10.1002/stem.2795
doi: 10.1002/stem.2795
Ding, H., & Wu, T. (2018). Insulin-like growth factor binding proteins in autoimmune diseases. Frontiers in Endocrinology, 9. https://doi.org/10.3389/fendo.2018.00499
Ahangar, P., et al. (2020). Mesenchymal stem cell secretome as an emerging cell-free alternative for improving wound repair. International journal of molecular sciences, 21(19), 7038. https://doi.org/10.3390/ijms21197038
doi: 10.3390/ijms21197038
Nair, R. R., et al. (2018). LPS-challenged macrophages release microvesicles coated with histones. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.01463
Chen, R., et al. (2014). Release and activity of histone in diseases. Cell Death & Disease, 5(8), e1370–e1370. https://doi.org/10.1038/cddis.2014.337
doi: 10.1038/cddis.2014.337
Levi, N., et al. (2020). The ECM path of senescence in aging: components and modifiers. The FEBS Journal, 287(13), 2636–2646. https://doi.org/10.1111/febs.15282
doi: 10.1111/febs.15282
Kortlever, R. M., et al. (2006). Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biology, 8(8), 877–884. https://doi.org/10.1038/ncb1448
doi: 10.1038/ncb1448
Vaughan, D. E., et al. (2017). Plasminogen activator inhibitor-1 is a marker and a mediator of senescence. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(8), 1446–1452. https://doi.org/10.1161/ATVBAHA.117.309451
doi: 10.1161/ATVBAHA.117.309451
Hardy, S. A., et al. (2019). Novel role of extracellular matrix protein 1 (ECM1) in cardiac aging and myocardial infarction. PLoS ONE, 14(2), e0212230. https://doi.org/10.1371/journal.pone.0212230
doi: 10.1371/journal.pone.0212230
Nishimura, N., et al. (2021). Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proceedings of the National Academy of Sciences of the United States of America, 118(17). https://doi.org/10.1073/pnas.2019633118
Feru, J., et al. (2016). Aging decreases collagen IV expression in vivo in the dermo-epidermal junction and in vitro in dermal fibroblasts: Possible involvement of TGF-β1. European Journal of Dermatology, 26(4), 350–360. https://doi.org/10.1684/ejd.2016.2782
doi: 10.1684/ejd.2016.2782
Ratushnyy, A., et al. (2020). Secretome of senescent adipose-derived mesenchymal stem cells negatively regulates angiogenesis. International Journal of Molecular Sciences, 21(5), 1802. https://doi.org/10.3390/ijms21051802
doi: 10.3390/ijms21051802
Ritschka, B., et al. (2017). The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes & Development, 31(2), 172–183. https://doi.org/10.1101/gad.290635.116
doi: 10.1101/gad.290635.116
Demaria, M., et al. (2014). An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Developmental cell, 31(6), 722–733. https://doi.org/10.1016/j.devcel.2014.11.012
doi: 10.1016/j.devcel.2014.11.012